Evidence map›Paper›PMID 32905177›Full record

ArticleCurrent oncology (Toronto, Ont.)2020

Does dissemination of guidelines alone increase the use of palliative single-fraction radiotherapy? Initial report of a longitudinal change management campaign at a provincial cancer program.

J O Kim, N Hanumanthappa, Y T Chung, J Beck, R Koul, B Bashir, A Cooke, A Dubey, J Butler, M Nashed and 2 more

Abstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

J O KimRadiation Oncology, CancerCare Manitoba, Winnipeg.
N HanumanthappaRadiation Oncology, CancerCare Manitoba, Winnipeg.
Y T ChungRady Faculty of Health Sciences, University of Manitoba, Winnipeg.
J BeckMedical Physics, CancerCare Manitoba, Winnipeg.
R KoulRadiation Oncology, CancerCare Manitoba, Winnipeg.
B BashirRadiation Oncology, CancerCare Manitoba, Winnipeg.
A CookeRadiation Oncology, CancerCare Manitoba, Winnipeg.
A DubeyRadiation Oncology, CancerCare Manitoba, Winnipeg.
J ButlerRadiation Oncology, CancerCare Manitoba, Winnipeg.
M NashedRadiation Oncology, CancerCare Manitoba, Winnipeg.
W HunterRadiation Oncology, Western Manitoba Cancer Centre, Brandon, MB.
A OngRadiation Oncology, CancerCare Manitoba, Winnipeg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite level 1 evidence demonstrating the equivalence of single-fraction radiotherapy (sfrt) and multiple-fraction radiotherapy (mfrt) for the palliation of painful bone metastases, sfrt remains underused. In 2015, to encourage the sustainable use of palliative radiation oncology resources, CancerCare Manitoba disseminated, to each radiation oncologist in Manitoba, guidelines from Choosing Wisely Canada (cwc) that recommend sfrt. We assessed whether dissemination of the guidelines influenced sfrt use in Manitoba in 2016, and we identified factors associated with mfrt. Methods: All patients treated with palliative radiotherapy for bone metastasis in Manitoba from 1 January 2016 to 31 December 2016 were identified from the provincial radiotherapy database. Patient, treatment, and disease characteristics were extracted from the electronic medical record and tabulated by fractionation schedule. Univariable and multivariable logistic regression analyses were performed to identify risk factors associated with mfrt. Results: In 2016, 807 patients (mean age: 70 years; range: 35-96 years) received palliative radiotherapy for bone metastasis, with 69% of the patients having uncomplicated bone metastasis. The most common primary malignancies were prostate (27.1%), lung (20.6%), and breast cancer (15.9%). In 62% of cases, mfrt was used-a proportion that was unchanged from 2015. On multivariable analysis, a gastrointestinal [odds ratio (or): 5.3] or lung primary (or: 3.3), complicated bone metastasis (or: 4.3), and treatment at a subsidiary site (or: 4.4) increased the odds of mfrt use. Conclusions: Dissemination of cwc recommendations alone did not increase sfrt use by radiation oncologists in 2016. A more comprehensive knowledge translation effort is therefore warranted and is now underway to encourage increased uptake of sfrt in Manitoba.

Indexed as

AdultAgedAged, 80 and overChange ManagementFemaleHumansMaleMiddle AgedNeoplasmsPalliative CareRadiation Oncologybehaviour changebone metastasisguideline adherenceknowledge translationpalliationquality improvementSingle-fraction radiotherapy

Identifiers

PMID32905177
PMCPMC7467795

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.